Kornimate/medical-research-clean huggingface dataset:
leukemia stem cell detection in acute myeloid leukemia

Conditions: Acute Myeloid Leukemia (AML)

Summary: most patients with acute myeloid leukemia (aml) achieve complete remission (cr) following induction chemotherapy. however, a large majority subsequently relapse and succumb to the disease. currently, cytogenetics and molecular aberrations are the best prognostic indicators; however, these factors cannot prognosticate accurately for individual patients. overall, the majority of patients with favorable or intermediate-risk aml will experience relapse. prognosis after relapse is dismal with a five-year overall survival rate of less than 10%. a leukemia stem cell (lsc) paradigm may explain this failure of cr to reliably translate into cure. this study is undertaken to determine whether the presence of lscs has prognostic value as well as to determine whether the presence of lscs has predictive value. this study has an observational component, whereby we intent evaluate whether the presence or absence of lscs is prognostic. this study also has an interventional component in which it uses lsc status to determine whether favorable and intermediate risk aml patients in cr receive consolidation with chemotherapy or allogeneic hct.


Eligibility criteria:
inclusion criteria: 1. must have previously signed the specimen procurement protocol consent associated with the leukemia stem cell assay ("step 1 informed consent") prior to starting aml therapy. 2. age 18 years and older 3. new diagnosis of aml, other than apl, confirmed by bone marrow aspirate/biopsy and reviewed by an institutional hematopathologist 4. completion of induction therapy, as defined by the investigator and post-induction bone marrow biopsy. exclusion criteria: 1. any debilitating medical or psychiatric illness that would preclude ability to follow study procedures. 2. indeterminate leukemia stem cell assay results at diagnosis.
influence of the spinal manipulation on muscle spasticity and manual dexterity in cerebral palsy.

Conditions: Cerebral Palsy, Spastic

Summary: the aim of the study is to evaluate a short term influence of the spinal manipulation (sm) on the wrist muscles spasticity and manual dexterity in children with spastic cerebral palsy. effect of sm and imitation of the sm has to be compared in the double-blinded randomized clinical trial.

muscle spasticity is an important clinical syndrome of cerebral palsy (cp) resulting from upper motor neuron lesion, and its reduction is a significant therapeutic target for optimizing motor performance. investigator's recent study describes decrease in spasticity after sm in a group of children with cp. but that case series has no control group and the sample size was small so it does not prove the influence of the sm on the muscle spasticity. the purpose of the present study is to evaluate influence of the sm on muscle spasticity and on manual dexterity of the child with cp in a double-blind randomized clinical trial with two arms: sm (experimental group) and imitation of sm (control group). children admitted to the international clinic of rehabilitation are selected according to inclusion-exclusion criteria and invited to participate. after getting the permission the baseline assessment is performed. patients are allocated to the experimental or control group using stratified randomization. medical doctor certified in manual therapy performs the intervention (sm in the experimental group and imitation in the control group) and in 15 minutes the second assessment is performed. investigators, children and parents are blinded to group allocation.

Eligibility criteria:
inclusion criteria: * spastic uni-, bilateral cerebral palsy * manual ability classification level (macs) - i-iii level * modified ashworth scale (mas) grade 1-3 in wrist or fingers flexors exclusion criteria: * dyskinetic or ataxic syndrome * less than 40 degrees of passive wrist extension with fingers extended * botox injections in hand muscles during last year or recent antispastic drugs * fracture in hand or forearm less than 6 month prior to examination * uncooperative behavior, inability to understand and comply with instructions * severe pain preventing the child from being able to complete examinations

Keywords: cerebral palsy spinal manipulation muscle spasticity manual dexterity
tucatinib plus trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for her2+ gastrointestinal cancers

Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma

Summary: this trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, folfox, and capox). it will look at what side effects happen when participants take this combination of drugs. a side effect is anything the drug does other than treating cancer. it will also look at whether tucatinib works with these drugs to treat certain types of cancer. the participants in this trial have her2-positive (her2+) cancer in their gut, stomach, intestines, or gallbladder (gastrointestinal cancer).


Eligibility criteria:
inclusion criteria: * participants must have an unresectable or metastatic solid malignancy that is histologically or cytologically confirmed to be one of the tumor types listed below: * cohorts 1a, 1b, 1c, and 1d * crc * gastric adenocarcinoma * gej adenocarcinoma * esophageal adenocarcinoma * cholangiocarcinoma * gallbladder carcinoma * cohorts 1e, 1f, 1g, and 2a * gastric adenocarcinoma * gej adenocarcinoma * esophageal adenocarcinoma * cohort 2b * crc * participants must be candidates to receive an oxaliplatin-based regimen as part of their standard-of-care treatment for all cohorts, except cohort 1g. * her2+ disease, as determined by historic or local laboratory testing * phase 1b cohorts: measurable or non-measurable disease according to recist v1.1 as determined by the investigator * phase 2 cohorts: measurable disease according to recist v1.1 as determined by the investigator * eastern cooperative oncology group performance status score of 0 or 1. exclusion criteria: * history of known hypersensitivity to planned study treatment * known to be positive for hepatitis b or c * for cohorts 2a and 2b: prior anti-her2 therapies * for cohorts 1e, 1f, 1g, 2a: prior therapy with an anti-pd-1, anti-pd-l1, or anti pd l2 agent or with an agent directed to another stimulatory or co-inhibitory t-cell receptor (eg, ctla-4, ox 40, cd137), and was discontinued from that treatment due to a grade 3 or higher immune-related adverse event (irae) there are additional inclusion criteria. the study center will determine if criteria for participations are met.

Keywords: her2+ her2-positive crc gastric cancer esophageal cancer seattle genetics
juvenile dermatomyositis

Conditions: Juvenile Dermatomyositis

Summary: this is a retrospective descriptive cross-sectional and observational multicenter clinical and progressive study of juvenile dermatomyositis. the aim is to determine the clinical, paraclinical, and evolutive characteristics and therapeutic modalities from a series of juvenile dermatomyositis identified in alsace between 2000 to 2015.


Eligibility criteria:
inclusion criteria: * age under 16 years * have a dermatomyositis according to the diagnostic criteria of bohan and peter of 1975 exclusion criteria: * refusal to participate in the study

Keywords: juvenile dermatomyositis inflammatory myopathy clinical features treatment
argon plasma coagulation scalpel on surgical treatment of breast cancer

Conditions: Breast Neoplasms

Summary: the investigators are selecting sixty (60) with breast cancer diagnoses where the surgical treatment is indicated.furthermore the investigators divided in two groups : 1) surgical treatment using regular electric scalpel ; 2) surgical treatment using argon plasma coagulation scalpel. our primary goal is to measure the bleeding during the surgery using the weight of the surgical tissues used. secondary we'll evaluate the immediate post operative outcomes, like infection, hematomas and seromas. all these variables will be evaluated by a doctor using our standard clinical record and it will be measured using reliable parameters, for exemple: if the investigators clinically detect a hematoma then we'll perform an ultrasound to take the real extension; if the investigators clinically pick an infection we'll measure the extension of the hiperemia; and if the investigators clinically pick a seroma we'll drain and quantify it. secondary the investigators going to evaluate and measure (centimeters) the terminal damage caused on the surgical specimens (samples) using the microscope.


Eligibility criteria:
inclusion criteria: * operable breast cancer exclusion criteria: * coagulation disturbs
combination therapy for first line treatment of advanced cervical cancer

Conditions: Advanced Cervical Cancer

Summary: this is a single center phase 1 trail to observe safety and efficacy of paclitaxel plus cisplatin\\carboplatin, pd-l1 antibody toripalimab and anlotinib as first-line regimen to treat the patient with metastatic 、persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both (stage ia-iva).

advanced cervical cancer patients with metastatic, persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both will be treated by paclitaxel plus cisplatin\\carboplatin, pd-l1 antibody toripalimab and anlotinib.

Eligibility criteria:
inclusion criteria: 1. female patients aged≥18 years. 2. histologically confirmed cervical squamous cell carcinoma or adenocarcinoma, without uncontrolled pleural effusion or ascites. 3. patients with advanced or metastatic disease who have disease progression after radical surgery、radical platinum-based concurrent chemoradiotherapy or both （stage ia-iva）, with measurable lesions. 4. ecog performance status 0 or 2, expected lifetime≥3 months. 5. adequate organ function: absolute neutrophil count (anc) ≥1.5x109/l, white blood count ≥3.5x109/l, platelets ≥100x109/l, hemoglobin (hb) ≥100g/l, alt/ast ≤2.5x uln (for patient with liver metastasis alt/ast ≤5x uln), serum bilirubin ≤1.5x uln, serum creatinine ≤1.5x uln. 6. hbv infected patients (inactive/asymptomatic carrier, chronic or active) with hbv dna\<500iu/ml (or 2500 copies/ml). 7. pregnancy test of female patients with fertile activity should be negative within 7 days before enrollment. patients should keep contraception during treatment. 8. willingness and ability to comply with the protocol for the duration of the study including scheduled visits, examinations, investigations and treatment plans with informed consent form. exclusion criteria: 1. pregnancy or children bearing potential. 2. brain or meningeal metastasis. 3. with second primary malignant diseases. 4. with uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or patients who should receive long-term glucocorticoid treatment (\>10mg/d prednisone). 5. with uncontrollable complications 6. inadequate organ function 7. conditions which impact on pill taking (dysphagia, chronic diarrhea, bowel obstruction). 8. known hypersensitivity reaction to any of the study drugs or components. 9. other unsuitable conditions determined by investigators.
multisession radiosurgery in residual/recurrent grade ii meningiomas.

Conditions: Meningioma Atypical

Summary: fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.

meningioma is the most common intracranial tumor (1). world health organization (who) grade ii (atypical) meningioma recurs more frequently than who grade i (benign) meningioma, and patients with subtotally resected atypical meningioma should be treated with adjuvant radiation therapy (2). however, many atypical meningiomas can be gross totally resected, and whether to administer radiation to this population remains unclear. apart from extent of resection, clinical characteristics such as age and gender and tumor-related characteristics such as tumor size and location have poor predictive capacity to determine which lesions will recur. the lack of professional consensus on the role of adjuvant radiation therapy (rt) derived from the heterogeneity and retrospective nature of the published data: standard fractionation fails to demonstrate a benefit in term of local control and survival. recent advances in radiotherapy technology (staged radiosurgery) give the possibility to reach high dose levels only in tumor volume and in the same time to save the surrounding healthy tissues. the purpose of this study is to verify the related toxicity of a new radiotherapy protocol and as second end point to evaluate the efficacy on disease local control at 3 years.

Eligibility criteria:
inclusion criteria: * patients had residual or recurrent atypical meningioma (grade ii) after surgery (simpson score) * age: ≥ 18 years old * karnofsky performance status ( kps) ≥ 70 * written consent exclusion criteria: * pregnancy * neurofibromatosis type 2 (nf2) * concomitant aggressive haematological or solid neoplasm

Keywords: atypical meningioma radiosurgery multisession radiosurgery recurrence meningioma
unsupported arm exercise and breathing strategy in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: controlling the way people with lung problems breathe during arm exercises may reduce their breathlessness during activities of daily living that require them to lift their arms (i.e. brushing their hair, putting groceries away on high shelves). the main aim of this study is to determine the effects of specific breathing strategies during arm exercise on dyspnoea in patients with chronic lung disease. coordinating inspiration with the action of arm elevation will reduce dyspnoea during a rhythmic overhead arm activity


Eligibility criteria:
inclusion criteria: * diagnosis of copd including forced expiratory volume in one second \< 80% predicted normal * presence of lung hyperinflation at rest exclusion criteria: * musculoskeletal or neurological condition which could adversely affect arm activity

Keywords: lung diseases, obstructive breathing exercises exercise tolerance dyspnea arm exercise
treatment of cml patients with imatinib and hydroxyurea (cml2004)

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Summary: the study will test the tolerability and efficacy of the combination therapy imatinib/hydroxyurea (hu) in patients with chronic myeloid leukemia (cml) in first chronic phase (cp1) newly diagnosted or failing interferon-based therapy.

the protocol consists of a part 1, a phase i study that will enrol 20 patients, with the goal to determine the safety of the combination as well as the maximal tolerated dose. if the toxicity of the combination is acceptable, up to 200 more patients may be recruited and randomized to receive either imatinib/hu or imatinib alone (part 2). patients who meet the inclusion criteria will be started on 400 mg imatinib daily. in part 1 of the protocol, the dose of hu will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. in part 2 of the study, patients will be randomized to receive either the combination or imatinib monotherapy. hematological and cytogenetic response will be evaluated at 3-months intervals during the first year, and at 6 months' intervals thereafter. primary endpoints for part 1 are dose-limiting toxicity and maximal tolerated dose. primary endpoints for part 2 are the rates of major and complete molecular response at 6, 12 and 18 months, respectively.

Eligibility criteria:
inclusion criteria: 1. ph-positive cml in cp1, newly diagnosed or resistant (hematologic or cytogenetic) or intolerant to interferon-based therapy 2. age ≥ 18 years 3. negative pregnancy test 4. low- and intermediate risk patients younger than 45 with an hla (human leukocyte antigen) -matched sibling donor and medically fit to undergo allografting should be included only after they have been adequately counselled about the potential risk (of disease progression) associated with delaying the allograft 5. informed consent exclusion criteria: 1. objective signs of disease progression beyond cp1 defined as * bone marrow or peripheral blood blasts \> 15% and/or * blasts + promyelocytes ≥ 30% and/or * peripheral blood basophils ≥ 20% and/or * platelets \< 100/nl and/or * chromosomal abnormalities in addition to the ph chromosome 2. findings suggestive of extramedullary involvement 3. any severe and uncontrolled medical condition 4. previous treatment with imatinib (only part 2 of the study) 5. history of non-compliance 6. simultaneous inclusion in other studies important note: previous treatment with imatinib only is not an exclusion criterion for part 1 of the study.
crestor rush (the efficacy of rosuvastatin for korean dyslipidemia patients with hypertension )

Conditions: Dyslipidemia; Hypertension

Summary: to evaluate the efficacy of rosuvastatin in korean dyslipidemia patients with hypertension.


Eligibility criteria:
inclusion criteria: * hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria 1. over 18 years of age 2. currently or previously diagnosed with hypertension and receiving medical care exclusion criteria: 1. patients already taking other hyperlipidemic agents 2. patients who do not fulfil the indication criteria for statin therapy 3. patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Keywords: dyslipidemia hypertension rosuvastatin efficacy naturalistic observational
cultural adaptation of a behavioral intervention for latino caregivers

Conditions: Alzheimer Disease; Dementia

Summary: the overall objectives of the proposed research are to: (i) develop a prototype of a smartphone application (app) that can deliver culturally adapted star-c training to latino caregivers, and (ii) understand the extent to which a star-c app is acceptable and potentially effective among latino caregivers. achieving these objectives will lay the groundwork for a future full-scale trial to test the star-c app with latino caregivers. this study aims to: adapt the star-c training to increase cultural relevance for latino caregivers. the adaptations will focus on incorporating cultural examples, identities, values, beliefs, and practices within the training, as well as using cultural idioms, metaphors, and sayings to compliment explanations. develop a prototype of a star-c app for latino caregivers. the prototype will be iteratively developed with active participation from latino caregivers. the final prototype will consist of a fully interactive app that delivers culturally relevant star-c training in an engaging and easy to use format. assess the acceptability and potential effectiveness of the star-c app for latino caregivers. measures of acceptability will include app usage and perceived ease-of-use and usefulness of the star-c app. measures of potential effectiveness will include changes in caregiver burden and depression.

for aim 1, the investigators plan to recruit 25-30 participants with representation from both caregivers and providers. the investigators will recruit latino family caregivers of persons with adrd (alzheimer's disease and related dementias). the investigators will recruit providers who work in an organization serving latino elderly. participants will be \>18 years old. for aim 2, the investigators will recruit 5 caregivers per session. with three iterative design sessions, the investigators anticipate 15 caregivers in total. the investigators will use the same eligibility criteria described for aim 1. for aim 3, the investigators will recruit 15 latino caregivers for each study arm (total sample size of 30). the investigators based the sample size on a rule of thumb of 12 to 15 participants per group for pilot studies. the investigators will use the same eligibility criteria and recruitment strategy described for aim 1

Eligibility criteria:
inclusion criteria: * aged 18 years or older * family member or close friend of a person with adrd * provide at least eight hours of care per week speak english or spanish * self-identify as latino. exclusion criteria: * caregiver who has a diagnosis of adrd

Keywords: latino caregiver cultural adaptation
laparoscopic approach to cancer of the endometrium

Conditions: Endometrial Cancer

Summary: the primary objective of this study is to assess disease-free survival at 4.5 years postoperatively for women with apparent stage 1 endometrial cancer, comparing patients who are randomised to receive total laparoscopic hysterectomy (tlh) and patients who are randomised to receive total abdominal hysterectomy (tah).

this phase iii international, multicenter, open-label, randomized clinical trial is an equivalence study with the hypothesis is that total laparoscopic hysterectomy (tlh) is associated with equivalent disease-free survival when compared to the standard treatment of total abdominal hysterectomy (tah) for women with apparent stage i endometrial cancer. the secondary hypotheses are: * tlh is associated with equivalent or improved quality of life (qol) at 6 months; * tlh is associated with reduced treatment-related morbidity; * tlh is associated with shorter hospital stay; * tlh is associated with less analgesic consumption; * tlh is cost effective; * tlh is associated with improved pelvic floor function.

Eligibility criteria:
inclusion criteria: patients who may be included for this study must have the following: * histologically confirmed primary endometrioid adenocarcinoma of the endometrium; * clinical stage i disease; * ecog performance status of 0-1; * signed written informed consent; * females, aged 18 years or older. exclusion criteria: patients will be excluded from participating from the study if they have any of the following: * other histologic type than endometrioid adenocarcinoma of the endometrium; * clinically advanced disease (stages ii-iv); * uterine size larger than 10 weeks gestation; * estimated life expectancy of less than 6 months; * enlarged aortic lymph nodes; * unfit for surgery: serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator); * patient compliance and geographic proximity that does not allow adequate follow-up; * unfit to complete qol measurements.

Keywords: endometrial endometrium uterus cancer carcinoma adenocarcinoma stage 1 hysterectomy laparoscopy abdominal total surgery quality of life disease-free survival